1.中国医科大学附属第一医院药学部,沈阳 110001
2.中国医科大学附属第一医院老年医学中心,沈阳 110001
3.中国医科大学智能医学学院,沈阳 110001
4.沈阳药科大学临床药学院,沈阳 110001
Received:05 June 2025,
Revised:2025-09-18,
Accepted:23 September 2025,
Published:15 November 2025
移动端阅览
郭静文,田文,张博瑒,等.驻科药师主导的药物治疗管理模式在老年心血管内科的应用与效果评价[J].中国药房,2025,36(21):2718-2722.
GUO Jingwen,TIAN Wen,ZHANG Bochang,et al.Application and effectiveness evaluation of resident clinical pharmacist-led medication therapy management model in geriatric cardiology departments[J].ZHONGGUO YAOFANG,2025,36(21):2718-2722.
郭静文,田文,张博瑒,等.驻科药师主导的药物治疗管理模式在老年心血管内科的应用与效果评价[J].中国药房,2025,36(21):2718-2722. DOI: 10.6039/j.issn.1001-0408.2025.21.17.
GUO Jingwen,TIAN Wen,ZHANG Bochang,et al.Application and effectiveness evaluation of resident clinical pharmacist-led medication therapy management model in geriatric cardiology departments[J].ZHONGGUO YAOFANG,2025,36(21):2718-2722. DOI: 10.6039/j.issn.1001-0408.2025.21.17.
目的
2
探讨驻科药师主导的药物治疗管理(MTM)模式在老年医学中心心血管内科的应用效果,为优化驻科药学服务提供参考。
方法
2
采用回顾性队列研究,纳入2023年3-8月(传统组,
n
=903)与2024年3-8月(MTM组,
n
=963)我院老年医学中心心血管内科住院患者的数据。传统组患者仅接受常规药学服务(处方前置审核、事后医嘱点评),MTM组患者在常规服务基础上,接受驻科药师主导的药物重整、治疗药物监测(TDM)、静脉输液规范化管理的MTM服务。通过比较两组患者的主要结局指标(如静脉输液率、TDM达标率等)和次要结局指标[如药物相互作用(DDIs)发生率、3级及以上急性肾损伤发生率、人均住院时长及人均总药费等
]
评估MTM模式实施效果。
结果
2
与传统组相比,在主要结局指标方面,MTM组患者的总静脉输液使用率、抑酸类药物注射剂使用率均显著降低(
P
<0.05),地高辛、万古霉素TDM达标率均显著升高(
P
<0.05);在次要结局指标方面,MTM组患者3级及以上急性肾损伤发生率、DDIs发生率、非医嘱离院率、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、胆固醇及人均总药费均显著降低(
P
<0.05),肌酐、估算的肾小球滤过率均显著升高(
P
<0.05),人均住院时长显著缩短(
P
<0.05)。
结论
2
驻科药师主导的MTM模式能有效优化药物治疗流程,提升用药安全性与经济性,对促进合理用药、改善患者结局具有积极作用。
OBJECTIVE
2
To investigate the effectiveness of resident clinical pharmacist-led medication therapy management (MTM) model in geriatric cardiology departments, and provide reference for optimizing resident pharmaceutical services.
METHODS
2
A retrospective cohort study was conducted, incorporating data from inpatients admitted to the Department of Cardiovascular Medicine in the Geriatric Medical Center of our hospital during March to August 2023 (conventional group,
n
=903) and the same period in 2024 (MTM group,
n
=963). The conventional group received only standard pharmaceutical services (including prospective prescription review and retrospective order evaluation), while the MTM group received additional resident clinical pharmacist-led interventions-such as medication reconciliation, personalized therapeutic drug monitoring (TDM), standardized intravenous infusion management, an
d a four-stage closed-loop monitoring process-based on conventional care. The effectiveness of the MTM model was evaluated by comparing the primary outcome measures (e.g., intravenous infusion rate, TDM target attainment rate) and secondary outcome measures [e.g., incidence of drug-drug interactions (DDIs), incidence of grade 3 or higher acute kidney injury, average length of hospital stay, cholesterol, and medication cost per capita
]
between the two groups.
RESULTS
2
Compared with the conventional group, in terms of primary outcome indexes: both the overall intravenous infusion rate and the use rate of acid-suppressive injection were significantly lowered in the MTM group (
P
<0.05); serum concentration target attainment rates for digoxin and vancomycin were increased significantly (
P
<0.05). For secondary outcome indexes, the MTM group exhibited significant decreases in the incidence of grade 3 or higher acute kidney injury, the incidence of DDIs, the rate of patients leaving the hospital against medical advice, alanine amino-transferase, aspartate transferase and the per capita total medication cost (
P
<0.05). Additionally, there was a notable increase in the creatinine, estimated glomerular filtration rate and a significant shortening of the per capita length of hospital stay (
P
<0.05).
CONCLUSIONS
2
The resident clinical pharmacist-led MTM model can significantly optimize medication therapy processes, enhance medication safety and cost-effectiveness, thus playing a positive role in promoting rational drug use and improving patient outcomes.
KIM J , PARISH A L . Polypharmacy and medication ma- nagement in older adults [J ] . Nurs Clin North Am , 2017 , 52 ( 3 ): 457 - 468 .
CALDERÓN-LARRAÑAGA A , VETRANO D L , ONDER G , et al . Assessing and measuring chronic multimorbidity in the older population:a proposal for its operationalization [J ] . J Gerontol A Biol Sci Med Sci , 2017 , 72 ( 10 ): 1417 - 1423 .
齐元涛 , 柳言 , 杜金 , 等 . 基于健康生态学模型的我国老年人慢性病共病影响因素研究 [J ] . 中国全科医学 , 2023 , 26 ( 1 ): 50 - 57 .
WHITTY C J M , MACEWEN C , GODDARD A , et al . Rising to the challenge of multimorbidity [J ] . BMJ , 2020 , 368 : l6964 .
WASTESSON J W , MORIN L , TAN E C K , et al . An update on the clinical consequences of polypharmacy in older adults:a narrative review [J ] . Expert Opin Drug Saf , 2018 , 17 ( 12 ): 1185 - 1196 .
BÜLOW C , CLAUSEN S S , LUNDH A , et al . Medication review in hospitalised patients to reduce morbidity and mortality [J ] . Cochrane Database Syst Rev , 2023 , 1 ( 1 ): CD008986 .
MANGIN D , BAHAT G , GOLOMB B A , et al . International group for reducing inappropriate medication use & polypharmacy (IGRIMUP):position statement and 10 recommendations for action [J ] . Drugs Aging , 2018 , 35 ( 7 ): 575 - 587 .
FERRERI S P , HUGHES T D , SNYDER M E . Medication therapy management:current challenges [J ] . Integr Pharm Res Pract , 2020 , 9 : 71 - 81 .
曾平 , 朱鸣雷 , 曲璇 , 等 . 治疗老年共病患者的重要模式:多学科整合团队 [J ] . 中华老年多器官疾病杂志 , 2013 , 12 ( 5 ): 336 - 338 .
IE K , HIROSE M , SAKAI T , et al . Medication optimization protocol efficacy for geriatric inpatients:a rando- mized clinical trial [J ] . JAMA Netw Open , 2024 , 7 ( 7 ): e2423544 .
王辉 , 赵付英 , 姜岳 . 全科医生主导的多学科团队服务模式管理老年人共病的实践与思考 [J ] . 中华全科医师杂志 , 2019 , 18 ( 8 ): 798 - 800 .
邓利娟 , 颜志婷 . 运用筛选工具评价老年共病患者药物相关问题的临床研究 [J ] . 药品评价 , 2022 , 19 ( 20 ): 1256 - 1259 .
国家卫生健康委办公厅 . 国家卫生健康委办公厅关于开展驻科药师工作模式试点的通知:国卫办医政函 〔2024〕 12 号[EB/OL ] .( 2024-01-10 )[ 2025-01-01 ] . https://www.sohu.com/a/788325144_121894856 https://www.sohu.com/a/788325144_121894856 .
YIN X , SONG F J , GONG Y H , et al . A systematic review of antibiotic utilization in China [J ] . J Antimicrob Chemother , 2013 , 68 ( 11 ): 2445 - 2452 .
KURLANDER J E , LAINE L , KIM H M , et al . Impact of large scale,multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system:difference-in-difference study [J ] . BMJ , 2024 , 385 : e076484 .
WANG C Q , XU J , JIANG H , et al . The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion:a clustered systematic review and meta-analysis [J ] . Phytomedicine , 2023 , 115 : 154847 .
ONDER G , VETRANO D L , PALMER K , et al . Italian guidelines on management of persons with multimorbidity and polypharmacy [J ] . Aging Clin Exp Res , 2022 , 34 ( 5 ): 989 - 996 .
SCOTT I A , REEVE E , HILMER S N . Establishing the worth of deprescribing inappropriate medications:are we there yet? [J ] . Med J Aust , 2022 , 217 ( 6 ): 283 - 286 .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
